KR20230083894A - Composition for prevention, improvement or treatment of coronavirus infection comprising hemp seed and black ginseng extract as active ingredients - Google Patents
Composition for prevention, improvement or treatment of coronavirus infection comprising hemp seed and black ginseng extract as active ingredients Download PDFInfo
- Publication number
- KR20230083894A KR20230083894A KR1020210172308A KR20210172308A KR20230083894A KR 20230083894 A KR20230083894 A KR 20230083894A KR 1020210172308 A KR1020210172308 A KR 1020210172308A KR 20210172308 A KR20210172308 A KR 20210172308A KR 20230083894 A KR20230083894 A KR 20230083894A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- virus
- mixture
- black ginseng
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 244000025254 Cannabis sativa Species 0.000 title claims abstract description 50
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 title claims abstract description 50
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 title claims abstract description 50
- 235000009120 camo Nutrition 0.000 title claims abstract description 50
- 235000005607 chanvre indien Nutrition 0.000 title claims abstract description 50
- 239000011487 hemp Substances 0.000 title claims abstract description 50
- 235000020710 ginseng extract Nutrition 0.000 title claims abstract description 29
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 19
- 239000004480 active ingredient Substances 0.000 title claims abstract description 10
- 230000002265 prevention Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 50
- 241000700605 Viruses Species 0.000 claims abstract description 30
- 241000711573 Coronaviridae Species 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 229940088598 enzyme Drugs 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 102000004139 alpha-Amylases Human genes 0.000 claims description 8
- 108090000637 alpha-Amylases Proteins 0.000 claims description 8
- 229940024171 alpha-amylase Drugs 0.000 claims description 8
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 101710130006 Beta-glucanase Proteins 0.000 claims description 6
- 108010059892 Cellulase Proteins 0.000 claims description 6
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 6
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 3
- 241001678559 COVID-19 virus Species 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000014644 Brain disease Diseases 0.000 abstract description 5
- 208000010643 digestive system disease Diseases 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- 208000019423 liver disease Diseases 0.000 abstract description 5
- 208000023504 respiratory system disease Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000241 respiratory effect Effects 0.000 abstract description 4
- 230000001079 digestive effect Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 19
- 241000208340 Araliaceae Species 0.000 description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 description 16
- 235000008434 ginseng Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 208000025721 COVID-19 Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000699800 Cricetinae Species 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 241001493065 dsRNA viruses Species 0.000 description 5
- 238000002481 ethanol extraction Methods 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- WOGWYSWDBYCVDY-UHFFFAOYSA-N 2-chlorocyclohexa-2,5-diene-1,4-dione Chemical compound ClC1=CC(=O)C=CC1=O WOGWYSWDBYCVDY-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 4
- 229940096437 Protein S Drugs 0.000 description 4
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 4
- 101710198474 Spike protein Proteins 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 241000711443 Bovine coronavirus Species 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 햄프씨드 추출물과 흑삼의 추출물을 유효성분으로 함유하는, 코로나 바이러스 감염의 예방, 경감 또는 치료용 약학적 조성물 및 코로나 바이러스 감염의 예방 또는 개선용 식품 조성물에 관한 것으로서, 본 발명에 따른 조성물은 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 바이러스인 코로나 바이러스, 특히 코로나-19 바이러스에 우수한 항바이러스 활성을 나타내므로, 코로나 바이러스의 감염에 의한 질환의 예방, 개선 또는 치료를 위한 의약품 및 식품 등에 유용하게 이용될 수 있다.The present invention relates to a pharmaceutical composition for preventing, reducing or treating coronavirus infection and a food composition for preventing or improving coronavirus infection, containing hemp seed extract and black ginseng extract as active ingredients, the composition according to the present invention Since it shows excellent antiviral activity against corona virus, especially the corona-19 virus, which is a virus that causes respiratory, digestive, liver and brain diseases, etc., it is a medicine for preventing, improving or treating diseases caused by corona virus infection And it can be usefully used for food, etc.
Description
본 발명은 햄프씨드와 흑삼 추출물을 이용한 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물에 관한 것으로서, 보다 상세하게는 햄프씨드와 흑삼 추출물의 혼합물, 이 혼합물의 효소 처리물, 이 혼합물의 발효물 등을 유효성분으로 하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving or treating coronavirus infection using hemp seed and black ginseng extract, and more particularly, a mixture of hemp seed and black ginseng extract, an enzyme-treated product of this mixture, a fermented product of this mixture, etc. It relates to a composition for preventing, improving or treating corona virus infection using as an active ingredient.
코로나 바이러스(corona virus)는 포유류와 조류에서 호흡기질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 RNA 바이러스이다(Gallagher TM. et.al., Virology, 279(2):371-374, 2001). 특히, 코로나 바이러스에 속하는 바이러스 중에서 돼지 전염성 위장염 바이러스(TGEV, transmissble gastroenteritis virus)와 돼지 유행성 설사 바이러스(PEDV, porcine epidemic diarrhea virus)는 매우 전염성이 높은 바이러스성 질병으로 위장관 소화기 계통에 침입하여 구토, 설사로 인한 탈수와 고열을 일으키며 치사율도 높아서 상당한 경제적 손실을 유발하는 바이러스이다(Duarte M. et.al., J Gen Virol., 75 (Pt 5):1195-1200, 1994). Corona virus is an RNA virus that causes respiratory, digestive, liver and brain diseases in mammals and birds (Gallagher TM. et.al., Virology, 279(2):371-374, 2001) . In particular, among the viruses belonging to the corona virus, transmissble gastroenteritis virus (TGEV) and porcine epidemic diarrhea virus (PEDV) are highly contagious viral diseases that invade the gastrointestinal tract and cause vomiting and diarrhea. It is a virus that causes dehydration and high fever due to high fever and a high mortality rate, causing considerable economic loss (Duarte M. et.al., J Gen Virol., 75 (Pt 5): 1195-1200, 1994).
이들 바이러스는 치사율이 매우 높음에도 다른 바이러스 감염으로 인한 질병처럼 확실한 치료제가 개발되어 있지 않은 실정이다.Although these viruses have a very high mortality rate, there is no reliable treatment for diseases caused by other viral infections.
코로나 바이러스에 의한 코로나 바이러스 감염증-19(coronavirus disease 2019, COVID-19) 또는 코로나-19는 2019년 12월 중국 우한에서 처음 발생한 이후 중국 전역과 전 세계로 확산된, 새로운 유형의 코로나 바이러스(SARSCoV-2; Coronaviridae에 속하는 RNA 바이러스)에 의한 호흡기 감염 질환이다. Coronavirus disease 2019 (COVID-19) caused by coronavirus, or COVID-19, is a new type of coronavirus (SARSCoV- 2; RNA virus belonging to Coronaviridae) is a respiratory infection disease.
초기에는 원인을 알 수 없는 호흡기 전염병으로만 알려졌으나, 세계보건기구(WHO)가 2020년 1월 9일 해당 폐렴의 원인이 새로운 유형의 코로나 바이러스(SARS-CoV-2, 국제바이러스분류위원회 2월 11일 명명)라고 밝히면서 병원체가 확인됐다.Initially, it was known only as a respiratory infectious disease of unknown cause, but on January 9, 2020, the World Health Organization (WHO) confirmed that the cause of the pneumonia was a new type of coronavirus (SARS-CoV-2, International Committee on Taxonomy of Viruses in February). Named on the 11th), the pathogen was confirmed.
코로나 바이러스 감염증-19의 병원체는 '사스-코로나 바이러스-2(SARS-CoV-2)'이다. 국제바이러스분류위원회(ICTV)는 2020년 2월 11일 코로나-19의 병원체에 SARS-CoV-2라는 이름을 제안한 논문을 발표했는데, 위원회는 이 바이러스가 2003년 유행한 사스(SARS, 중증급성호흡기증후군)와 비슷하다는 점을 강조한 것이라고 밝혔다.The pathogen of COVID-19 is 'SARS-CoV-2'. The International Committee on Taxonomy of Viruses (ICTV) published a paper on February 11, 2020 proposing the name SARS-CoV-2 for the pathogen of COVID-19. syndrome) and emphasized the similarity.
우리나라는 중국이 학계를 통해 공개한 해당 바이러스의 유전자 염기서열을 입수해 분석한 결과 박쥐 유래 유사 코로나 바이러스와 가장 높은 상동성(89.1%)이 있음을 확인하였다. 사람 코로나 바이러스 4종과의 상동성은 39%~43%로 낮았으며, 메르스와는 50%, 사스와는 77.5%의 상동성을 확인하였다.Korea obtained and analyzed the gene sequence of the virus disclosed by China through academia, and as a result, it was confirmed that it had the highest homology (89.1%) with a similar bat-derived coronavirus. The homology with the four human corona viruses was low at 39% to 43%, and 50% with MERS and 77.5% with SARS were confirmed.
현재 전 세계적으로 문제되고 있는 코로나 바이러스 감염증-19(Coronavirus disease 2019, COVID-19) 질환은 신종 코로나 바이러스(Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) 감염에 의한 호흡기 증후군이라 정의되고 있으며, 질병 분류는 법정감염병 제1급감염병 신종 감염병 증후군 및 질병 코드는 U07.1이다.Corona virus disease 2019 (COVID-19), which is currently a problem worldwide, is defined as a respiratory syndrome caused by infection with a new coronavirus (Severe acute
병원체는 SARS-CoV-2로써 Coronaviridae에 속하는 RNA 바이러스이고, 전파 경로는 현재까지 비말(침방울) 내지 접촉으로, 기침이나 재채기를 할 때 생긴 비말을 통한 전파 또는 코로나 바이러스에 오염된 물건을 만진 뒤 눈, 코, 입을 만져 전파가 주를 이룬다.The pathogen is SARS-CoV-2, an RNA virus belonging to Coronaviridae, and the transmission route has been droplets (saliva droplets) or contact so far, spread through droplets produced when coughing or sneezing, or after touching objects contaminated with coronavirus. , the nose and mouth are mainly transmitted by touching.
코로나 바이러스 감염으로 인한 전 세계 치명률은 평균 약 3.4% (WHO, 3.5 기준)이며, 현재 전 세계적으로 감염자의 6%가 사망자로 등록될 만큼 국가별·연령별 치명률 수준은 매우 상이하며, 고령, 면역기능이 저하된 환자, 기저 질환을 가진 환자에서 주로 중증 및 사망을 초래한다.The global fatality rate due to corona virus infection is about 3.4% on average (based on WHO, 3.5), and currently, 6% of infected people worldwide are registered as dead, so the level of fatality rate by country and age is very different. This deterioration causes severe illness and death, mainly in patients with underlying diseases.
코로나 바이러스는 단쇄 양성 가닥(single positive strand)의 나선형 구조(helical structure)를 가지는 RNA 바이러스로써 총 5개의 구조 단백으로 구성되어 있으며, 이중 spike glycoprotein(S protein)에 의해 전자현미경 상에서 마치 왕관이나 후광이 있는 것처럼 관찰된다(Schoeman and Fielding, 2019). 코로나 바이러스는 27-34KB로 현존하는 RNA 바이러스 중 제일 zmu, 알파, 베타, 델타, 감마의 4군으로 세분화되어있고, 이중 베타군이 전염성과 병독성이 높다. Corona virus is an RNA virus with a single positive strand helical structure and consists of a total of 5 structural proteins. It is observed as if it exists (Schoeman and Fielding, 2019). Corona virus is subdivided into 4 groups of zmu, alpha, beta, delta, and gamma among existing RNA viruses with 27-34 KB, and the beta group is highly contagious and virulence.
SARS-CoV-2는 표면에 존재하는 S protein이 숙주 세포의 angiotensin converting enzyme 2(ACE2)에 결합하면서 침입하며, ACE2는 구강과 비강 점막, 비인두, 폐, 위, 소장, 대장 등에 많이 분포하고 있어 바이러스성 폐렴 소견이 관찰되는 특징이 있다(Hamming et al., 2004).SARS-CoV-2 invades when the S protein present on the surface binds to angiotensin converting enzyme 2 (ACE2) of host cells, and ACE2 is widely distributed in the oral and nasal mucosa, nasopharynx, lung, stomach, small intestine, and large intestine. It is characterized by the observation of viral pneumonia (Hamming et al., 2004).
코로나 바이러스의 잠복기는 1~14일(평균 4~7일)이고, 진단 기준으로는 진단을 위한 검사기준에 따라 검체에서 바이러스 분리 또는 검체에서 특이 유전자를 검출하여 진단하고 있다. The incubation period of coronavirus is 1 to 14 days (average 4 to 7 days), and diagnosis is made by isolating the virus from a sample or detecting a specific gene in a sample according to the test criteria for diagnosis.
코로나 바이러스 감염증-19의 증상으로는 발열, 권태감, 기침, 호흡곤란 및 폐렴 등 경증에서 중증까지 다양한 호흡기 감염증이 나타나며, 그 외 가래, 인후통, 두통, 객혈과 오심, 설사 등도 나타난다. 현재 수액 보충, 해열제 등 보존적 치료를 하는 것 외에 특이적인 항바이러스제가 없는 것이 현실이며, 세계보건기구(World Health Organization, WHO)는 SARS-CoV-2에 대한 항체가 있더라도 재감염과 코로나 바이러스 감염증-19 질병 감염으로부터 보호될 수 있다는 증거가 없다고 발표하여 치료제 개발의 중요성이 부각되는 계기가 되었다.Symptoms of COVID-19 include various respiratory infections ranging from mild to severe, such as fever, malaise, cough, shortness of breath, and pneumonia, as well as phlegm, sore throat, headache, hemoptysis, nausea, and diarrhea. Currently, there is no specific antiviral drug other than conservative treatment such as fluid supplementation and antipyretics, and the World Health Organization (WHO) has confirmed that even if there is an antibody to SARS-CoV-2, reinfection and coronavirus infection- 19 It was announced that there was no evidence that it could be protected from disease infection, which served as an opportunity to highlight the importance of developing a treatment.
본 발명자는 햄프씨드 추출물과 흑삼 추출물의 유효성을 연구하던 중에 햄프씨드에 대한 흑삼의 상승 작용에 의해 햄프씨드 단독으로 사용하였을 때보다 햄프씨드 추출물과 흑삼 추출물을 함께 사용하였을 때 Vero-E6 세포에 SARS-CoV-2 바이러스를 감염시켰을 때 바이러스 감염 및 복제 억제 효과, SARS-CoV-2에 감염된 햄스터의 체온 증가와 체중 감소 저해 효과 및 SARS-CoV-2에 감염된 햄스터에서 SARS-CoV-2 스파이크 단백질 결합 활성 억제 효과가 현저하게 상승하는 하는 것을 확인하여 코로나 바이러스의 복제 및 감염 억제용 조성물로서의 본 발명을 완성한 것이다.While studying the effectiveness of hemp seed extract and black ginseng extract, the present inventors found that the synergistic effect of black ginseng on hemp seed caused SARS in Vero-E6 cells when hemp seed extract and black ginseng extract were used together rather than when hemp seed alone was used. -Inhibiting viral infection and replication when infected with CoV-2 virus, increasing body temperature and inhibiting weight loss in hamsters infected with SARS-CoV-2, and binding to SARS-CoV-2 spike protein in hamsters infected with SARS-CoV-2 The present invention as a composition for inhibiting replication and infection of coronavirus was completed by confirming that the activity inhibitory effect significantly increased.
따라서 본 발명이 해결하고자 하는 과제는 햄프씨드 추출물과 흑삼 추출물의 혼합물을 유효성분으로 함유하는, 코로나 바이러스 감염의 예방, 경감 또는 치료용 조성물을 제공하는 것이다.Therefore, the problem to be solved by the present invention is to provide a composition for preventing, reducing or treating coronavirus infection, containing a mixture of hemp seed extract and black ginseng extract as an active ingredient.
상기 과제를 해결하기 위하여, 본 발명은 햄프씨드 추출물과 흑삼 추출물의 혼합물을 유효성분으로 함유하는 코로나 바이러스, 바람직하게는 코로나-19 바이러스(SARS-CoV-2) 감염의 예방, 경감 또는 치료용 약학적 조성물 내지 건강식품 조성물을 제공한다.In order to solve the above problems, the present invention is a pharmaceutical for preventing, reducing or treating corona virus, preferably corona-19 virus (SARS-CoV-2) infection, containing a mixture of hemp seed extract and black ginseng extract as an active ingredient. Red composition to provide a health food composition.
상술한 바와 같은 본 발명에 따른 조성물에서, 상기 햄프씨드 추출물과 흑삼 추출물의 추출 용매가 물 또는 에탄올인 것이 바람직하다.In the composition according to the present invention as described above, it is preferable that the extraction solvent of the hemp seed extract and the black ginseng extract is water or ethanol.
상술한 바와 같은 본 발명에 따른 조성물에서 상기 햄프씨드 추출물과 흑삼 추출물의 혼합물은 베타-칼락토시다제(β-galactosidase), 베타-글루코시다제(β-glucosidase), 베타-글루카나제(β-glucanase), 알파-아밀라제(α-amylase) 및 셀룰라제(cellulase)로 이루어진 군에서 선택되는 어느 하나 이상의 효소로 처리한 것임을 특징으로 한다.In the composition according to the present invention as described above, the mixture of the hemp seed extract and the black ginseng extract is beta-galactosidase, beta-glucosidase, beta-glucanase (β-galactosidase) -glucanase), alpha-amylase, and cellulase.
상술한 바와 같은 본 발명에 따른 조성물에서 상기 햄프씨드 추출물과 흑삼 추출물의 혼합물은 유산균 또는 효모로 발효한 것임을 특징으로 하다.In the composition according to the present invention as described above, the mixture of the hemp seed extract and the black ginseng extract is characterized in that it is fermented with lactic acid bacteria or yeast.
상술한 바와 같은 본 발명에 따른 조성물에서 상기 햄프씨드 추출물과 흑삼 추출물의 혼합물은 효소로 처리한 후 유산균 또는 효모로 발효한 것임을 특징으로 한다.In the composition according to the present invention as described above, the mixture of the hemp seed extract and the black ginseng extract is characterized in that it is fermented with lactic acid bacteria or yeast after being treated with an enzyme.
상술한 바와 같은 본 발명에 따른 조성물에서 상기 햄프씨드 추출물과 흑삼 추출물의 혼합 비율은 햄프씨드 100중량부에 대하여 흑삼 5 내지 10중량부인 것이 바람직하다.In the composition according to the present invention as described above, the mixing ratio of the hemp seed extract and the black ginseng extract is preferably 5 to 10 parts by weight of black ginseng based on 100 parts by weight of the hemp seed.
본 발명의 조성물은 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 바이러스인 코로나 바이러스, 특히 코로나-19 바이러스에 우수한 항바이러스 활성을 나타내므로, 코로나 바이러스의 감염에 의한 질환의 예방, 개선 또는 치료를 위한 의약품 및 식품 등에 유용하게 이용될 수 있다.The composition of the present invention exhibits excellent antiviral activity against corona virus, especially the corona-19 virus, which is a virus that causes respiratory diseases, digestive diseases, liver diseases, brain diseases, etc. It can be usefully used for medicines and foods for treatment.
도 1 및 4는 본 발명의 조성물을 이용하여 Vero-E6 숙주세포에 대한 코로나 바이러스 감염 억제 효과를 나타낸 것이다.
도 2 및 도 5는 본 발명의 조성물을 이용하여 코로나 바이러스에 감염된 Vero-E6 숙주세포에 대한 바이러스 복제 억제 효과를 나타낸 것이다.
도 3 및 6은 본 발명의 조성물을 이용하여 SARS-CoV-2에 감염된 햄스터에서 SARS-CoV-2 스파이크 단백질 결합 활성 억제 효과를 나타낸 것이다.1 and 4 show the inhibitory effect of coronavirus infection on Vero-E6 host cells using the composition of the present invention.
2 and 5 show the effect of inhibiting viral replication on Vero-E6 host cells infected with coronavirus using the composition of the present invention.
3 and 6 show the effect of inhibiting SARS-CoV-2 spike protein binding activity in hamsters infected with SARS-CoV-2 using the composition of the present invention.
이하 본 발명을 실시하기 위한 구체적인 내용을 상세하게 설명하기로 한다.Hereinafter, specific details for carrying out the present invention will be described in detail.
본 발명은 햄프씨드 추출물과 흑삼 추출물의 혼합물, 이 혼합물의 효소 처리물, 이 혼합물의 발효물 등을 유효성분으로 하여, 코로나 바이러스 감염을 예방, 개선 또는 치료할 수 있는 조성물에 관한 것으로서, 본 발명의 조성물을 사용하여 Vero-E6 세포에서 SARS-CoV-2 바이러스에 대한 감염 억제 및 복제 억제 시험을 진행한 결과 유의적인 결과를 확인하였으며, 또한, 코로나 바이러스 감염 햄스터 모델에서 SARS-CoV-2의 spike protein binding activity(스파이크 단백질 결합 활성)을 확인한 결과 매우 우수하게 활성도가 감소하는 것을 확인하였으며, 시험동물의 체온증가 억제와 체중 감소 억제를 확인하였다. 이에 따라 본 발명의 조성물은 SARS-CoV-2의 스파이크 단백질 결합 활성 억제를 통해 세포의 코로나 바이러스의 감염을 억제하는 것으로 나타났으며, 이는 독성이 없으면서 치료효과가 우수한 코로나 바이러스 감염 예방, 개선, 또는 치료용 조성물로 유효함을 시사한다.The present invention relates to a composition capable of preventing, improving or treating coronavirus infection, using a mixture of hemp seed extract and black ginseng extract, an enzyme-treated product of this mixture, a fermented product of this mixture, etc. as an active ingredient, Infection inhibition and replication inhibition tests for the SARS-CoV-2 virus were performed in Vero-E6 cells using the composition, and significant results were confirmed. In addition, the spike protein of SARS-CoV-2 in a coronavirus-infected hamster model As a result of confirming the binding activity (spike protein binding activity), it was confirmed that the activity was reduced very well, and the inhibition of body temperature increase and weight loss of the test animals was confirmed. Accordingly, the composition of the present invention has been shown to inhibit the infection of the cell coronavirus by inhibiting the spike protein binding activity of SARS-CoV-2, which is non-toxic and has excellent therapeutic effects in preventing, improving, or preventing corona virus infection. It suggests that it is effective as a composition for treatment.
따라서, 본 발명은 햄프씨드 추출물과 흑삼 추출물의 혼합물을 유효성분으로 포함하는 코로나 바이러스 감염의 예방 또는 치료용 약학적 조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition for preventing or treating coronavirus infection comprising a mixture of hemp seed extract and black ginseng extract as an active ingredient.
특히, 본 발명은 햄프씨드 코로나 바이러스에 대한 항바이러스 활성을 흑삼을 부가하여 햄프씨드에 대한 흑삼의 상승효과를 통하여 코로나 바이러스 감염 예방 또는 치료 효과를 현저하게 상승시킨 것을 특징으로 한다. In particular, the present invention is characterized in that the antiviral activity against hemp seed corona virus is significantly increased by adding black ginseng to prevent or treat corona virus infection through the synergistic effect of black ginseng on hemp seed.
본 발명에서, 상기 ‘코로나 바이러스’는 돼지 전염성 위장염 바이러스(TGEV, transmissble gastroenteritis virus), 돼지 유행성 설사 바이러스(PEDV, porcine epidemic diarrhea virus), 개 코로나 바이러스(canine coronavirus), 소 코로나 바이러스(bovine Coronavirus), 사스 코로 나바이러스(SARS-CoV) 및 코로나-19 바이러스(SARS-CoV-2)로 이루어진 군으로부터 선택되는 어느 하나 이상일 수 있다.In the present invention, the 'corona virus' includes transmissble gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), canine coronavirus, and bovine coronavirus , SARS coronavirus (SARS-CoV) and corona-19 virus (SARS-CoV-2) may be any one or more selected from the group consisting of.
또한, 본 발명은 햄프씨드 추출물과 흑삼 추출물의 혼합물을 유효성분으로 포함하는 코로나 바이러스 감염의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving corona virus infection comprising a mixture of hemp seed extract and black ginseng extract as an active ingredient.
본 발명에 사용되는 햄프씨드와 흑삼은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한이 없이 사용 가능하며, 이 햄프씨드와 흑삼을 용매 추출한 추출물, 바람직하게는 물 또는 에탄올을 추출 용매로 하여 추출한 추출물을 사용하는 것이다.The hemp seeds and black ginseng used in the present invention can be used without particular limitation as long as they are widely known in the art to which the present invention belongs, and the hemp seeds and black ginseng are solvent-extracted extracts, preferably extracted with water or ethanol as an extraction solvent. to use the extract.
또한, 발명의 추출 방법은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한이 없이 사용 가능하며, 그 예로는 가열추출법, 냉침 추출법, 환류냉각 추출법, 수증기 증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 선택하여 사용할 수 있으며, 또한 목적에 따라 추출물은 통상의 분획 공정을 수행할 수 있으며, 통상의 정제 방법에 따라 정제될 수 있다.In addition, the extraction method of the present invention can be used without particular limitation as long as it is widely known in the art to which the present invention belongs, and examples thereof include heating extraction, cold extraction, reflux cooling extraction, steam distillation, ultrasonic extraction, dissolution, compression, etc Depending on the purpose, the extract may be subjected to a conventional fractionation process and may be purified according to a conventional purification method.
또한, 추출된 1차 추출물을 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가 과정을 통해 분말화하여 제조할 수 있으며, 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography), 박층 크로마토그래피(thin layer chromatography) 등의 다양한 크로마토그래피를 통해 정제 분획을 얻을 수 있다. In addition, the extracted primary extract can be prepared by pulverization through additional processes such as distillation under reduced pressure and freeze drying or spray drying, and silica gel column chromatography, high performance liquid chromatography ), a purified fraction can be obtained through various chromatography such as thin layer chromatography.
따라서 본 발명에서 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분리 화합물, 분획 및 정제물, 이들의 희석, 농축, 건조물을 모두 포함하는 개념으로 이해할 수 있다.Therefore, in the present invention, the extract can be understood as a concept including all extracts, separated compounds, fractions and purified products obtained in each step of extraction, fractionation or purification, and dilution, concentration, and dried products thereof.
또한, 본 발명에서는 햄프씨드 추출물과 흑삼 추출물의 혼합물을 효소로 처리하거나 발효하여 사용할 수 있으며, 효소로 처리한 후 발효하여 사용할 수 있다.In addition, in the present invention, a mixture of hemp seed extract and black ginseng extract may be used after being treated with an enzyme or fermented, or may be used after being treated with an enzyme and then fermented.
본 발명에서 사용되는 효소는 베타-칼락토시다제(β-galactosidase), 베타-글루코시다제(β-glucosidase), 베타-글루카나제(β-glucanase), 알파-아밀라제(α-amylase) 및 셀룰라제(cellulase)로 이루어진 군에서 선택되는 어느 하나 이상인 것이 바람직하다.Enzymes used in the present invention include beta-galactosidase, beta-glucosidase, beta-glucanase, alpha-amylase, and It is preferably at least one selected from the group consisting of cellulase.
본 발명의 발효에 이용되는 균주는 햄프씨드와 흑삼을 발효하는 것으로 공지되어 있는 모든 균주를 이용할 수 있으며, 바람직하게는 유산균 또는 효모일 수 있다.The strain used in the fermentation of the present invention may use all strains known to ferment hemp seeds and black ginseng, preferably lactic acid bacteria or yeast.
구체적으로 본 발명에서 사용되는 추출물의 혼합물 제조는 Specifically, the preparation of the mixture of extracts used in the present invention
햄프씨드를 70 내지 100℃의 열수로 추출하는 추출단계 또는 햄프씨드를 70중량% 에탄올을 이용하여 추출하는 추출 단계로 통하여 햄프씨드 추출물을 준비하고 이와 동일한 방법으로 흑삼 추출물을 준비하여 이들을 일정한 비율로 균등하게 혼합하여 이루어진다Prepare a hemp seed extract through an extraction step of extracting hemp seeds with hot water at 70 to 100 ° C or an extraction step of extracting hemp seeds using 70% by weight ethanol, and prepare black ginseng extracts in the same way to prepare them in a certain ratio. It is made by mixing evenly
여기에서, 햄프씨드 추출물과 흑삼 추출물의 혼합 비율은 다양하게 설정될 수 있으나 햄프씨드 추출물의 항바이러스 효과를 상승시키기에 충분한 정도의 흑삼 추출물을 혼합하는 것이 바람직한데, 그 비율을 햄프씨드 추출물 100중량부에 흑삼 추출물 5 내지 15중량부인 것으로 본 발명자의 시험에 의해 확인되었다.Here, the mixing ratio of the hemp seed extract and the black ginseng extract can be set in various ways, but it is preferable to mix the black ginseng extract in an amount sufficient to increase the antiviral effect of the hemp seed extract. It was confirmed by the test of the present inventors that the black ginseng extract was 5 to 15 parts by weight.
또한, 제조 공정을 줄이기 위하여 햄프씨드와 흑삼을 추출 전에 혼합한 후에 추출하여 혼합물을 제조할 수도 있다.In addition, in order to reduce the manufacturing process, a mixture may be prepared by mixing hemp seeds and black ginseng before extraction and then extracting them.
또한, 본 발명에 따른 조성물은 상기 혼합물을 항바이러스 효과의 상승을 일으키는 효소 처리하거나 발효하는 단계를 더 진행하여 제조될 수 있다.In addition, the composition according to the present invention may be prepared by further processing the mixture with an enzyme that causes an increase in antiviral effect or fermentation.
상기 효소 처리는 추출물의 혼합물에 효소를 부가하고 25 내지 65℃에서 2 내지 7시간 동안 효소 처리하는 하는 것이며, 상기 발효 단계는 상기 혼합물에 유산균 또는 효모, 바람직하게는 사카로마이세스 크레비시아에( Saccharomyces cerevisiae)를 넣고 20 내지 40℃에서 10 내지 48시간 발효하는 것이다.The enzyme treatment is to add an enzyme to the mixture of extracts and enzymatically treat the mixture at 25 to 65 ° C. for 2 to 7 hours, and the fermentation step is to add lactic acid bacteria or yeast to the mixture, preferably to Saccharomyces crevisia. ( Saccharomyces cerevisiae ) is added and fermented at 20 to 40 ° C for 10 to 48 hours.
또한, 본 발명에 따른 조성물은 혼합물을 상술한 바와 같이 효소 처리를 한 후에 이어서 발효단계를 순차적으로 진행하는 방법으로 제조된 조성물도 포함한다.In addition, the composition according to the present invention also includes a composition prepared by a method of sequentially proceeding with a fermentation step after enzymatic treatment of the mixture as described above.
또한, 햄프씨드 추출물과 흑삼 추출물을 각각 상술한 바와 같은 방법으로 효소 처리 또는 발효 및 이들의 순차 진행을 한 후에 혼합하여 제조된 혼합물도 본 발명에 따른 조성물에 포함된다.Also included in the composition according to the present invention is a mixture prepared by mixing hemp seed extract and black ginseng extract after enzymatic treatment or fermentation, respectively, in the same manner as described above.
그리고 본 발명은 햄프씨드 추출물과 흑삼 추출물의 효과를 더욱 상승시키기 위하여 명자나무 열매 추출물을 더 부가할 수 있으며, 이때 명자나무 열매의 사용량은 흑삼 동일하며, 추출 방법은 햄프씨드와 흑삼 추출과 동일하다.In addition, in the present invention, in order to further increase the effect of the hemp seed extract and the black ginseng extract, the Myongja tree fruit extract can be further added. .
이하, 실시예 및 시험예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예 및 시험예는 오로지 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들에 의해 한정되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples and test examples. These examples and test examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
<< 실시예Example 1: 시료의 제조> 1: preparation of sample>
햄프씨드 추출물 100중량부에 대하여 흑삼 추출물 10중량부를 혼합한 혼합물, 이 혼합물을 알파-아밀라제(α-amylase)로 효소 처리한 효소 처리물, 이 혼합물을 알파-아밀라제(α-amylase)로 효소 처리한 다음 사카로마이세스 크레비시아에(Saccharomyces cerevisiae)로 발효한 발효물을 시료로 하였다.A mixture of 10 parts by weight of black ginseng extract mixed with 100 parts by weight of hemp seed extract, an enzyme-treated product obtained by enzymatically treating this mixture with α-amylase, and enzymatically treating this mixture with α-amylase Then, the fermentation product fermented with Saccharomyces cerevisiae was used as a sample.
구체적으로 상기 추출물은 70 내지 100℃의 열수로 추출하는 열수 추출물 또는 에탄올을 이용하여 추출물이며,Specifically, the extract is a hot water extract extracted with hot water at 70 to 100 ° C. or an extract using ethanol,
상기 효소 처리물은 추출물의 혼합물에 효소를 부가하고 45℃에서 3시간 동안 효소 처리하여 제조하였으며,The enzyme treatment was prepared by adding an enzyme to a mixture of extracts and treating the enzyme at 45 ° C. for 3 hours,
상기 발효물은 상술한 효소 처리가 완료된 혼합물에 사카로마이세스 크레비시아에(Saccharomyces cerevisiae)를 넣고 30℃에서 24시간 발효시키는 발효 단계를 통하여 제조하였다. 이에 따라 본 발명에 따른 시료의 조합을 아래와 같은 6가지로 하여 후술하는 시험에 사용하였음, 비교 시료는 햄프씨드만을 단독으로 하여 동일한 과정을 거친 6가지의 비교 시료를 준비하였다.The fermented product was prepared through a fermentation step in which Saccharomyces cerevisiae was added to the above-described enzyme-treated mixture and fermented at 30 ° C. for 24 hours. Accordingly, the six combinations of samples according to the present invention were used in the test described later as follows. Six comparative samples were prepared using only hemp seeds alone and subjected to the same process.
<본 발명에 따른 시료 리스트><Sample list according to the present invention>
시료 1: 햄프씨드 열수 추출물과 흑삼 열수 추출물의 혼합물Sample 1: A mixture of hemp seed hot water extract and black ginseng hot water extract
시료 2: 햄프씨드 에탄올 추출물과 흑삼 에탄올 추출물의 혼합물Sample 2: A mixture of hemp seed ethanol extract and black ginseng ethanol extract
시료 3: 시료 1 혼합물 효소 처리물Sample 3: Sample 1 mixture enzyme treatment
시료 4: 시료 2 혼합물의 효소 처리물Sample 4: enzyme treatment of
시료 5: 시료 3 효소 처리물의 발효물Sample 5: fermented product of sample 3 enzyme treatment
시료 6: 시료 4 효소 처리물의 발효물Sample 6: fermented product of sample 4 enzyme treatment
<비교 시료 리스트><Comparative sample list>
비교 시료 1: 햄프씨드 열수 추출물Comparative Sample 1: Hemp Seed Hot Water Extract
비교 시료 2: 햄프씨드 에탄올 추출물Comparative Sample 2: Hemp Seed Ethanol Extract
비교 시료 3: 비교 시료 1 추출물 효소 처리물Comparative Sample 3: Comparative Sample 1 Extract Enzyme Treatment
비교 시료 4: 비교 시료 2 추출물의 효소 처리물Comparative Sample 4: Enzymatic Treatment of
비교 시료 5: 비교 시료 3 효소 처리물의 발효물Comparative sample 5: fermented product of comparative sample 3 enzyme treatment
비교 시료 6: 비교 시료 4 효소 처리물의 발효물Comparative Sample 6: Fermented product of Comparative Sample 4 enzyme treatment
<< 시험예test example 1: 바이러스 감염 억제 효과> 1: Virus infection inhibitory effect>
Vero-E6 세포는 DMEM(-/-)에서 배양되었으며 바이러스 감염 시험 시, 12 well-plate에 5×105cells/well의 농도로 접종하였다. 37℃, CO2 인큐베이터에서 24시간 동안 배양하고 세포 배지를 제거한 다음 1× PBS로 2회 수세하였다. Vero-E6 cells were cultured in DMEM (-/-) and were inoculated at a concentration of 5×10 5 cells/well in 12 well-plates for virus infection test. After culturing for 24 hours at 37° C. in a CO2 incubator, the cell medium was removed and washed twice with 1× PBS.
상기 100㎍/㎖의 농도의 시료로 전처리한 후 37℃, CO2 인큐베이터에서 2시간 동안배양하고, 이후 바이러스 감염을 위해 세포 배지를 제거한 다음 SARS-CoV-2 바이러스를 50pfu/well 농도로 1시간 동안 처리하였다. 이후 세포 배지를 제거한 뒤 배지 1.5㎖를 각 well에 추가하고 72시간 동안 반응시킨 뒤 결과를 확인하였다. After pre-treatment with the sample at a concentration of 100 μg/ml, incubation at 37° C. in a CO 2 incubator for 2 hours, then removing the cell medium for virus infection, and then incubating the SARS-CoV-2 virus at a concentration of 50 pfu/well for 1 hour. treated during. Then, after removing the cell medium, 1.5 ml of the medium was added to each well, reacted for 72 hours, and the result was confirmed.
이 때 SARS-CoV-2 바이러스에 대해 치료 효과가 있다고 알려진 렘데시비르(Remdesivir, Rem) 5μM과 말라리아 치료제 클로로퀴논 포스페이트(Chloroquinone phosphate, C.P) 10μM을 대조군으로 설정하여 시험을 진행하였다.At this time, 5 μM of Remdesivir (Rem), which is known to have a therapeutic effect on the SARS-CoV-2 virus, and 10 μM of chloroquinone phosphate (CP), a malaria treatment, were set as controls and the test was conducted.
도 1에 나타난 결과와 같이, 본 발명에 따른 시료는 대조군인 렘데시비르나 클로로퀴논 포스페이트에 비해서 현저하게 우수한 결과를 나타내었으며, 이와 비교하여 비교 시료의 경우도 대조군에 조금 못 미치는 정도의 항바이러스 효과만을 보여 본 발명에 따른 시료의 비교 시료에 대한 효과의 현저성을 확인할 수 있었으며, 이는 햄프씨드에 대한 흑삼의 상승효과를 입증하는 것이다.As shown in Figure 1, the sample according to the present invention showed significantly better results than the control group remdesivir or chloroquinone phosphate, and compared to this, the comparative sample also showed a slightly less antiviral level than the control group. Only the effect was shown, and the significance of the effect on the comparative sample of the sample according to the present invention was confirmed, which proves the synergistic effect of black ginseng on hemp seeds.
또한, 도 1을 보면 효소에 의한 처리를 한 시료와 발효한 시료에서 더욱 우수하였으며, 열수 추출과 에탄올 추출에서는 큰 차이를 보이지 않았다.In addition, referring to FIG. 1, the samples treated with enzymes and the samples fermented were more excellent, and there was no significant difference in hot water extraction and ethanol extraction.
<< 시험예test example 2: 바이러스 복제 억제 효과> 2: Virus replication inhibitory effect>
Vero-E6 세포는 DMEM(-/-)에서 배양되었으며, 12 well-plate에 5×105cells/well의 농도로 접종하였다. 37℃, CO2 인큐베이터에서 24시간 배양하고 세포 배지를 제거한 다음 1× PBS로 2회 수세하였다. 바이러스 감염을 위해 SARS-CoV-2 바이러스를 50pfu/well 농도로 1시간 동안 처리하였으며, 이후 상기 시료 100㎍/㎖가 함유된 배지 1.5㎖를 각 well에 추가하고 72시간 동안 반응시킨 뒤 결과를 확인하였다. Vero-E6 cells were cultured in DMEM (-/-) and inoculated at a concentration of 5×10 5 cells/well in 12 well-plates. After culturing for 24 hours in a 37°C, CO 2 incubator, the cell medium was removed and washed twice with 1×PBS. For virus infection, the SARS-CoV-2 virus was treated for 1 hour at a concentration of 50 pfu/well, then 1.5 ml of medium containing 100 μg/ml of the sample was added to each well, reacted for 72 hours, and the results were confirmed. did
이때 SARS-CoV-2 바이러스에 대해 치료 효과가 있다고 알려진 렘데시비르(Remdesivir, Rem) 5μM과 말라리아 치료제 클로로퀴논 포스페이트(Chloroquinone phosphate, C.P) 10μM을 대조군으로 설정하여 시험을 진행하여 그 결과를 도 2에 나타냈다.At this time, 5 μM of Remdesivir (Rem), which is known to have a therapeutic effect on the SARS-CoV-2 virus, and 10 μM of chloroquinone phosphate (C.P), a malaria treatment, were set as control groups and the test was conducted, and the results are shown in FIG. 2 shown in
도 2에 나타난 결과와 같이, 본 발명에 따른 시료에서는 모두 효과적인 SARS-CoV-2 바이러스의 복제 억제 효과를 나타냈으며, 세포독성 없이 항바이러스 효과를 나타내으며, 대조군인 클로로퀴논 포스페이트와 렘데시비르 보다도 매우 우수하며, 특히 햄프씨드만으로 제조된 비교 시료와 비교하였을 때 본 발명에 따른 시료의 효과 현저성을 확인할 수 있었다.As shown in FIG. 2, all of the samples according to the present invention exhibited an effective SARS-CoV-2 virus replication inhibitory effect, exhibited an antiviral effect without cytotoxicity, and were superior to the control groups chloroquinone phosphate and remdesivir. It is very excellent, and in particular, when compared to the comparative sample prepared only with hemp seeds, the effect of the sample according to the present invention was confirmed.
또한, 도 2를 보면 효소에 의한 처리를 한 시료와 발효한 시료에서 더욱 우수하였으며, 열수 추출과 에탄올 추출에서는 큰 차이를 보이지 않았다.In addition, referring to FIG. 2, the samples treated with enzymes and the fermented samples were more excellent, and there was no significant difference in hot water extraction and ethanol extraction.
<< 시험예test example 3: 항바이러스 효과> 3: Antiviral effect>
6주령 햄스터를 입수, 무작위로 그룹을 설정한 뒤 일주일간 안정화시킨 후 햄스터에 SARS-CoV-2를 감염시켰으며, 24시간 후 4일간 상기 시료를 100mg/kg의 농도로 경구 투여하였다. 바이러스 투여 전과 투여 후 4일간, 체중은 매일, 체온은 감염 전후로 1회씩 측정하였다.Six-week-old hamsters were obtained, groups were randomly set, and after stabilization for one week, the hamsters were infected with SARS-CoV-2, and after 24 hours, the sample was orally administered at a concentration of 100 mg/kg for 4 days. For 4 days before and after virus administration, body weight was measured every day, and body temperature was measured once before and after infection.
바이러스 투여 후 4일차에 햄스터의 타액을 수거하고 전처리 과정을 거친 뒤, SARS-CoV-2 Spike RBD Nanobody kit을 이용하여 스파이크 단백질(spike protein)의 결합 활성을 확인함으로써 항바이러스 효과를 측정하여 그 결과를 도 3에 나타냈다.On the 4th day after virus administration, the saliva of the hamster was collected and pre-treated, and the antiviral effect was measured by using the SARS-CoV-2 Spike RBD Nanobody kit to confirm the binding activity of the spike protein. is shown in Figure 3.
도 3에 나타난 바와 같이, 본 발명에 따른 시료는 바이러스의 결합 활성 억제 효과를 나타냈으며, 특히 효소에 의한 처리를 한 시료와 발효한 시료에서 더욱 우수하였으며, 열수 추출과 에탄올 추출에서는 큰 차이를 보이지 않았다.As shown in FIG. 3, the sample according to the present invention showed the effect of inhibiting the binding activity of viruses, and in particular, the samples treated with enzymes and the fermented samples were more excellent, and there was no significant difference between hot water extraction and ethanol extraction. did not
특히, 햄프씨드만으로 제조된 비교 시료와 비교하였을 때 본 발명에 따른 시료의 효과 현저성을 확인할 수 있었다.In particular, when compared with the comparative sample prepared only with hemp seeds, the effect of the sample according to the present invention was confirmed.
<< 시험예test example 4: 해열 효과 및 체중감소 억제 효과> 4: antipyretic effect and weight loss inhibitory effect>
코로나 바이러스 감염증-19는 바이러스 감염으로 인한 발열을 동반하는데, 이에 따라 시험예 3 시험에서 감염 0 일차와 4 일차 되는 날 햄스터의 체온을 측정함으로써 코로나 바이러스감염증-19의 증상 완화 효과를 측정하여 그 결과를 표 1에 나타냈다.COVID-19 is accompanied by fever due to viral infection. Accordingly, in Test Example 3, the hamster's body temperature was measured on the 0th and 4th day of infection to measure the effect of alleviating the symptoms of COVID-19. is shown in Table 1.
상기 표 1에 나타난 바와 같이, 코로나 바이러스 감염에 의해 체온이 증가하였으나, 본 발명에 따른 시료의 투여로 인해 체온 증가가 억제되는 것을 확인하였으며, 특히 효소에 의한 처리를 한 시료와 발효한 시료에서 더욱 우수하였으며, 열수 추출과 에탄올 추출에서는 큰 차이를 보이지 않았다.As shown in Table 1, although body temperature increased due to corona virus infection, it was confirmed that the increase in body temperature was suppressed due to the administration of the sample according to the present invention, especially in samples treated with enzymes and fermented samples. It was excellent, and there was no significant difference between hot water extraction and ethanol extraction.
특히, 햄프씨드만을 사용한 비교 시료는 대조군과 차이가 거의 없어 증상 완화 효과가 매우 미비하여 본 발명에 따른 시료와 확연한 차이를 보였다. In particular, the comparison sample using only hemp seeds had little difference from the control group, and the symptom relief effect was very insignificant, showing a clear difference from the sample according to the present invention.
또한, 코로나 바이러스 감염증-19는 바이러스 감염으로 인한 체중감소를 유발하는데, 이에 따라 시험예 3 시험에서 감염 0 일차부터 4 일차 되는 날까지 총 5회 햄스터 체중을 측정함으로써 체중감소 억제 효과를 측정하여 그 결과를 표 2에 나타냈다.In addition, COVID-19 causes weight loss due to viral infection. Accordingly, in Test Example 3, the weight loss inhibitory effect was measured by measuring the weight of hamsters a total of 5 times from the 0th day of infection to the 4th day. The results are shown in Table 2.
상기 표 2에 나타난 바와 같이, 코로나 바이러스 감염에 의해 체중이 감소하였으나, 본 발명에 따른 시료 투여로 인해 체중 감소가 억제되는 것을 확인하였으며, 특히 효소에 의한 처리를 한 시료와 발효한 시료에서 더욱 우수하였으며, 열수 추출과 에탄올 추출에서는 큰 차이를 보이지 않았다.As shown in Table 2, although the weight was decreased due to corona virus infection, it was confirmed that the weight loss was suppressed due to the sample administration according to the present invention, especially in the samples treated with enzymes and the fermented samples. There was no significant difference between hot water extraction and ethanol extraction.
또한, 햄프씨드만을 사용한 비교 시료는 대조군과 차이가 거의 없어 증상 완화 효과가 매우 미비하여 본 발명에 따른 시료와 확연한 차이를 보였다. In addition, the comparison sample using only hemp seeds had little difference from the control group, and the symptom relief effect was very insignificant, showing a clear difference from the sample according to the present invention.
상기 시험예들을 통해 본 발명의 흑삼 추출물은 SARS-CoV-2 바이러스에 대하여 유의미한 감염 및 복제 억제효과를 나타내었다. 또한, 햄스터에 바이러스를 감염시킨 뒤 체중, 체온, SARS-CoV-2 스파이크 단백질 결합 능력을 확인함으로써 뛰어난 항바이러스 효능이 있음을 확인하였다.Through the above test examples, the black ginseng extract of the present invention showed significant infection and replication inhibitory effects against the SARS-CoV-2 virus. In addition, after infecting the hamster with the virus, it was confirmed that there is an excellent antiviral efficacy by checking the body weight, body temperature, and SARS-CoV-2 spike protein binding ability.
상기 시험예를 종합하였을 때, 본 발명에 따른 조성물은 SARS-CoV-2의 RNA 복제 억제와 단백질 결합능력 저해를 통해 코로나 바이러스를 억제하는 것으로 예측되며, 특히 햄프씨드에 대한 흑삼의 병용 투여 효과는 현저한 것을 확인할 수 있었다.When the above test examples are put together, the composition according to the present invention is predicted to inhibit the coronavirus through inhibition of RNA replication and protein binding ability of SARS-CoV-2, and in particular, the effect of combined administration of black ginseng on hemp seeds is remarkable things could be observed.
따라서 본 발명에 따른 조성물은 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 바이러스인 코로나 바이러스, 특히 코로나-19 바이러스에 우수한 항바이러스 활성을 나타내므로, 코로나 바이러스의 감염에 의한 질환의 예방, 개선 또는 치료를 위한 의약품 및 식품 등에 유용하게 이용될 수 있다.Therefore, the composition according to the present invention exhibits excellent antiviral activity against corona virus, especially the corona-19 virus, which is a virus that causes respiratory diseases, digestive diseases, liver diseases, brain diseases, etc. It can be usefully used for medicines and foods for improvement or treatment.
<< 실시예Example 2: 시료의 제조> 2: preparation of sample>
햄프씨드 추출물 100중량부에 대하여 흑삼 추출물 10중량부와 명자나무 열매 추출물 10중량부를 혼합한 혼합물을 시료로 하였다.A mixture obtained by mixing 10 parts by weight of the black ginseng extract and 10 parts by weight of the fruit extract of the black ginseng with respect to 100 parts by weight of the hemp seed extract was used as a sample.
구체적으로 상기 추출물은 70 내지 100℃의 열수로 추출하는 열수 추출물 또는 에탄올을 이용하여 추출물이며, 이에 따라 본 발명에 따른 시료의 조합을 아래와 같은 2가지로 하여 상기 시험예와 동일하게 진행을 하여 그 결과를 도 4, 도 5, 도 6으로 나타냈다.Specifically, the extract is a hot water extract extracted with hot water at 70 to 100 ° C. or an extract using ethanol. Accordingly, the combination of the sample according to the present invention is performed in the same manner as in the above test example in the following two ways, The results are shown in Figs. 4, 5 and 6.
<본 발명에 따른 시료 리스트><Sample list according to the present invention>
시료 7: 햄프씨드 열수 추출물. 흑삼 열수 추출물 및 명자나무 열매 열수 추출물의 혼합물Sample 7: Hemp seed hot water extract. A mixture of hot water extract of black ginseng and hot water extract of ginseng fruit
시료 8: 햄프씨드 에탄올 추출물, 흑삼 에탄올 추출물 및 명자나무 열매 에탄올 추출물의 혼합물Sample 8: A mixture of hemp seed ethanol extract, black ginseng ethanol extract, and ethanol extract of Myrtle tree fruit
첨부한 도 4, 5, 6의 명자나무 열매가 추가된 시료 7과 8의 결과를 도 1. 2, 3과 비교하였을 때 시료 5와 6보다도 더 우수한 결과를 보여 명자나무 열매에 의한 상승효과를 충분히 확인할 수 있었다.When comparing the results of samples 7 and 8 to which the fruits of the Myongja tree of FIGS. 4, 5, and 6 were added with those of FIGS. enough to check.
따라서 명자나무 열매까지 포함하는 본 발명에 따른 조성물은 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 바이러스인 코로나 바이러스, 특히 코로나-19 바이러스에 우수한 항바이러스 활성을 나타내므로, 코로나 바이러스의 감염에 의한 질환의 예방, 개선 또는 치료를 위한 의약품 및 식품 등에 유용하게 이용될 수 있다.Therefore, the composition according to the present invention, including the fruit of the nutmeg tree, exhibits excellent antiviral activity against corona virus, especially the corona-19 virus, which is a virus that causes respiratory diseases, digestive diseases, liver diseases, brain diseases, etc. It can be usefully used for medicines and foods for preventing, improving or treating diseases caused by.
Claims (8)
A pharmaceutical composition for preventing, alleviating or treating coronavirus infection containing a mixture of hemp seed extract and black ginseng extract as an active ingredient.
A health food composition for preventing or improving corona virus infection containing a mixture of hemp seed extract and black ginseng extract as an active ingredient.
The composition according to claim 1 or 2, characterized in that the corona virus is the corona-19 virus (SARS-CoV-2).
The composition according to claim 1 or 2, wherein the extraction solvent used to prepare the extract is water or ethanol.
The method of claim 4, wherein the mixture is beta-galactosidase (β-galactosidase), beta-glucosidase (β-glucosidase), beta-glucanase (β-glucanase), alpha-amylase (α-amylase) ) And cellulase (cellulase) a composition characterized in that the treatment with any one or more enzymes selected from the group consisting of.
The composition according to claim 4, wherein the mixture is fermented with lactic acid bacteria or yeast.
The method of claim 4, wherein the mixture is beta-galactosidase (β-galactosidase), beta-glucosidase (β-glucosidase), beta-glucanase (β-glucanase), alpha-amylase (α-amylase) ) And cellulase (cellulase) and treatment with any one or more enzymes selected from the group consisting of, and then fermented with lactic acid bacteria or yeast composition characterized in that.
The composition according to claim 1 or 2, wherein the mixing ratio of the mixture is 5 to 15 parts by weight of the black ginseng extract based on 100 parts by weight of the hemp seed extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210172308A KR20230083894A (en) | 2021-12-03 | 2021-12-03 | Composition for prevention, improvement or treatment of coronavirus infection comprising hemp seed and black ginseng extract as active ingredients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210172308A KR20230083894A (en) | 2021-12-03 | 2021-12-03 | Composition for prevention, improvement or treatment of coronavirus infection comprising hemp seed and black ginseng extract as active ingredients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230083894A true KR20230083894A (en) | 2023-06-12 |
Family
ID=86770131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210172308A KR20230083894A (en) | 2021-12-03 | 2021-12-03 | Composition for prevention, improvement or treatment of coronavirus infection comprising hemp seed and black ginseng extract as active ingredients |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230083894A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101834872B1 (en) | 2016-09-09 | 2018-04-13 | 주식회사 제넨셀 | Pharmaceutical composition for prevention or treatment of alpha-type herpes virus infection comprising the extract of Elaeocarpus sylvestris or fraction thereof as an active ingredient |
-
2021
- 2021-12-03 KR KR1020210172308A patent/KR20230083894A/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101834872B1 (en) | 2016-09-09 | 2018-04-13 | 주식회사 제넨셀 | Pharmaceutical composition for prevention or treatment of alpha-type herpes virus infection comprising the extract of Elaeocarpus sylvestris or fraction thereof as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112930392B (en) | Probiotics for upper respiratory tract infections, stress, anxiety, memory and cognitive dysfunction and aging | |
| KR102204299B1 (en) | Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component | |
| CN116236580A (en) | Application of old medicines such as auranofin and the like and compositions thereof in resisting single positive strand RNA viruses | |
| KR102503431B1 (en) | Composition for preventing, improving or treating coronavirus infection containing black ginseng as an active ingredient | |
| EP2490703B1 (en) | Herbal composition comprising ginger and goldenrod for the treatment of influenza infection | |
| WO2005067940A1 (en) | Novel use of water soluble glucan oligomer isolated from saccharomyces cerevisiae is2 for prevention and treatment of avian flu | |
| CN113398219A (en) | Application of exocarpium citri rubrum extract for preparing medicine for inhibiting human coronavirus infection | |
| KR20230083894A (en) | Composition for prevention, improvement or treatment of coronavirus infection comprising hemp seed and black ginseng extract as active ingredients | |
| KR20230040961A (en) | Composition for preventing or treating coronavirus infection comprising Tetrandrine or its analogues | |
| US20230241144A1 (en) | Antiviral agent for preventing or treating covid-19 | |
| KR102570596B1 (en) | Composition for preventing or treating corona virus comprising Hoveniae Semen Cum Fructus extracts | |
| Nishihira et al. | Maitake mushrooms (Grifola frondosa) enhances antibody production in response to influenza vaccination in healthy adult volunteers concurrent with alleviation of common cold symptoms | |
| KR20240037390A (en) | Antiviral composition containing ginseng extract and steroid compound as active ingredients | |
| KR20210116151A (en) | Composition for preventing or treating coronavirus infection comprising steroidal derivatives comprising lactone ring | |
| TWI805237B (en) | Use of lactic acid bacteria for manufacturing an antiviral composition | |
| Saharan et al. | THE PANDEMIC-COVID 19-A RACE OF PHARMACEUTICALS | |
| TWI757735B (en) | Use of lactic acid bacteria for manufacturing an antiviral composition | |
| WO2009113464A1 (en) | Anti-influenza virus composition and food for preventing influenza | |
| KR102240693B1 (en) | Pharmaceutical composition comprising tetraarsenic hexoxide for preventing or treating coronavirus disease | |
| WO2022215827A1 (en) | Sanguisorba officinalis linne extract composition inhibiting 3cl protease and rdrp activity of sars-cov-2 | |
| RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
| Rozaliyani et al. | The Potential of Herbal Combinations as Adjunctive Therapy for Standard Care of COVID-19 Patients: A Lesson Learned from Indonesia | |
| KR20220139780A (en) | Sanguisorba officinalis Linne extract having a suppressive effect against enzymatic activity of the SARS-CoV-2 3C-like protease and RNA-dependent RNA Polymerase | |
| Liang et al. | Effects of refined Glycyrrhiza uralensis polysaccharide on intestinal flora and intestinal barrier function in broilers: High-throughput sequencing study | |
| Towa | A Review on Natural Products as A Possible Medicine for Covid 19 Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |